Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure

Cardio3 BioSciences Receives Authorization to Begin World’s First Phase III Clinical Trial in Regenerative Medicine for Heart Failure

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress

Cardio3 BioSciences Has Been Selected to Present C3BS-CQR-1 Trial Data in Late Breaking Clinical Trial Session at European Society of Cardiology 2012 Heart Failure Congress

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

Cardio3 BioSciences Announces CE Marking for its C-Cath® Injection Catheter

Cardio3 BioSciences Granted GMP Certification

Cardio3 BioSciences Granted GMP Certification

Cardio3 BioSciences Receives ISO-13485 Certification

Cardio3 BioSciences Receives ISO-13485 Certification

Cardio3 BioSciences Secures Additional €3.1 million in Non-dilutive Funding from the Walloon Region and the European Commission

Cardio3 BioSciences Secures Additional €3.1 million in Non-dilutive Funding from the Walloon Region and the European Commission